Jun 29, 2022 Elite Pharmaceuticals Receives FDA Approval For Generic Sabril® NORTHVALE, NJ / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet. LannettCompany, Inc. has an exclusive license to market and distribute the product in the U.S. and territories.
PS: And I didn't even mention LANNETT is our partner for Dantrolene..........and the partnership was JUST extended last year for an additional 2 YEARS.